Prof. Dr. med. Peter Fasching

Professur für Translationale Frauenheilkunde und Geburtshilfe

Clinical effectiveness and safety of olaparib in BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: final analysis of LUCY (2023) Balmaña J, Fasching P, Couch FJ, Delaloge S, Labidi-Galy I, O’Shaughnessy J, Park YH, et al. Journal article RANK and RANKL Expression in Tumors of Patients with Early Breast Cancer (2023) Behrens A, Wurmthaler L, Heindl F, Gaß P, Häberle L, Volz B, Hack C, et al. Journal article A likelihood ratio approach for utilizing case-control data in the clinical classification of rare sequence variants: Application to BRCA1 and BRCA2 (2023) Zanti M, O'Mahony DG, Parsons MT, Li H, Dennis J, Aittomäkkiki K, Andrulis IL, et al. Journal article Aktuelle Strategien zur Systemtherapie des frühen Mammakarzinoms von der 18. Internationalen St.-Gallen-Konsensuskonferenz (2023) Lüftner D, Banys-Paluchowski M, Ditsch N, Fasching P, Jackisch C, Janni W, Krug D, et al. Journal article Improved HER2 Tumor Segmentation with Subtype Balancing Using Deep Generative Networks (2023) Öttl M, Steenpaß J, Rübner M, Geppert CI, Qiu J, Wilm F, Hartmann A, et al. Conference contribution Multicenter evaluation of blood-based biomarkers for the detection of endometriosis and adenomyosis: A prospective non-interventional study (2023) Burghaus S, Drazic P, Wölfler M, Mechsner S, Zeppernick M, Meinhold-Heerlein I, Mueller MD, et al. Journal article Evaluation of European-based polygenic risk score for breast cancer in Ashkenazi Jewish women in Israel (2023) Levi H, Carmi S, Rosset S, Yerushalmi R, Zick A, Yablonski-Peretz T, Wang Q, et al. Journal article Patient-reported outcomes and hospitalization data in patients with HER2-positive metastatic breast cancer receiving trastuzumab deruxtecan or trastuzumab emtansine in the phase III DESTINY-Breast03 study (2023) Curigliano G, Dunton K, Rosenlund M, Janek M, Cathcart J, Liu Y, Fasching P, Iwata H Journal article Association Between Obesity and Circulating Tumor Cells in Early Breast Cancer Patients (2023) Tzschaschel M, Friedl TW, Schochter F, Schütze S, Polasik A, Fehm T, Pantel K, et al. Journal article Cost-Effectiveness of Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Single-Agent Pembrolizumab for High-Risk Early-Stage Triple-Negative Breast Cancer in the United States (2023) Huang M, Fasching P, Haiderali A, Xue W, Yang C, Pan W, Zhou ZY, et al. Journal article